摘要
目的:观察厄贝沙坦联合氨氯地平治疗对青年肥胖高血压患者血清瘦素水平及胰岛素敏感性的影响。方法:入选104例青年肥胖原发性高血压患者,应用厄贝沙坦150mg/d联合氨氯地平5mg/d(联合组,n=104例)治疗24周;另选取同期健康体检体重正常者为正常对照组(对照组,n=100),测定对照组及联合组治疗前后的体质量指数(BMI)、腰臀比值(WHR)、血压、血清瘦素水平、空腹血糖和空腹胰岛素,采用稳态模型评价胰岛素抵抗指数(HOMA-IR)。结果:治疗前联合组的血压、血清瘦素水平和HOMA-IR与对照组有明显的差异(P<0.05)。治疗24周后,联合组的血压、血清瘦素水平和HOMA-IR明显下降(P<0.05)。结论:厄贝沙坦联合氨氯地平可有效控制青年肥胖高血压患者的血压,且能改善与肥胖相关的代谢紊乱。
Objective To observe the effects of combination of irbesartan with amlodipine on serum leptin level and insulin sensitivity in young obesity - associated hypertensive patients. Method Total 104 young patients with obesity and hypertension treated with irbesartan（150mg/d） combined amlodipine （5mg/d） as combined group（ n = 104） for 24 weeks. And 100 normotensive health people as control group（n = 100）. BMI, WHR, blood pressure, serum leptin level, fasting blood glucose, fasting insulin level and HOMA -IR were assayed during the tests. Results Before treatment, blood pressure, the level of serum leptin and HOMA - IR in combined group showed sig nificant differences with control group（ P 〈 0. 05 ）. After treatment with irbesartan combined amlodipine, blood pressure, the level of serum leptin and HOMA - IR were decreased significantly in combined group（P 〈 0. 05 ）. Conclusion The combination of irbesartan and amlodipine is effective on blood pressure control in young obesity - associated hypertensive patients. The combination of these two compounds improves obesityrelated metabolism disorder.
出处
《吉林医学》
CAS
2009年第20期2385-2387,共3页
Jilin Medical Journal
基金
国家自然科学基金资助项目(项目编号:30871042)
关键词
厄贝沙坦
氨氯地平
肥胖高血压
瘦素
胰岛素抵抗
Irbesartan
Amlodipine
Obesity-associated Hypertension
Leptin
Insulin resistance
